vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners initiated coverage on vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target for the company.

vTv Therapeutics Stock Down 3.3 %

VTVT stock opened at $20.20 on Friday. The business has a 50 day moving average price of $15.68 and a two-hundred day moving average price of $15.09. The company has a market cap of $64.44 million, a price-to-earnings ratio of -4.46 and a beta of 0.73. vTv Therapeutics has a twelve month low of $8.10 and a twelve month high of $30.99.

Institutional Trading of vTv Therapeutics

A number of hedge funds have recently made changes to their positions in the business. FMR LLC acquired a new stake in shares of vTv Therapeutics in the third quarter valued at approximately $2,402,000. Geode Capital Management LLC lifted its position in shares of vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at approximately $25,000. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.